{
    "clinical_study": {
        "@rank": "80778", 
        "arm_group": [
            {
                "arm_group_label": "Exercise Intervention Arm", 
                "arm_group_type": "Experimental", 
                "description": "The exercise intervention will consist of a combination of aerobic (cardiovascular exercise) and strength training (emphasis of the intervention) 3 times per week for 12 weeks with each session lasting ~1.5 hours."
            }, 
            {
                "arm_group_label": "Non-Exercise Control Arm", 
                "arm_group_type": "No Intervention", 
                "description": "Participants in the Non-Exercise Control Arm will not exercise for 12 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This randomized pilot study will be conducted in men with metastatic castration resistant\n      prostate cancer (mCRPC) within 3 months of initiating abiraterone or enzalutamide.  The\n      purpose of this pilot study is to evaluate the effects of a 12 week exercise intervention in\n      mCRPC patients who have recently started on additional androgen suppression therapy."
        }, 
        "brief_title": "Randomized, Controlled Study of an Exercise Intervention Program for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Either Abiraterone or Enzalutamide", 
        "completion_date": {
            "#text": "May 2022", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Castration Resistant Prostate Cancer (mCRPC)", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This randomized pilot study will be conducted in men with metastatic castration resistant\n      prostate cancer (mCRPC) within 3 months of initiating abiraterone or enzalutamide.  The\n      purpose of this pilot study is to evaluate the effects of a 12 week exercise intervention in\n      mCRPC patients who have recently started on additional androgen suppression therapy. The\n      investigators will also explore the effects of the exercise training on biomarkers of\n      inflammation-hormonal status and their potential association with changes in lean mass and\n      function."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. \u226518 years of age\n\n          2. Metastatic disease that has progressed despite castrate levels of testosterone\n             (surgically or medically castrated, with testosterone levels of < 50 ng/dL)\n\n          3. No prior chemotherapy\n\n          4. Initiated therapy with either abiraterone plus a glucocorticoid or enzalutamide\n             within the 3 months prior to randomization\n\n          5. Ability to engage safely in moderate exercise as determined by their treating\n             physician\n\n          6. Not previously engaged in regular exercise training (>1-2 d/wk for > 30 min/d) in the\n             past 6 months\n\n          7. Be able to speak and read English\n\n        Exclusion Criteria:\n\n          1. Any condition that causes severe pain with exertion\n\n          2. History of bone fractures\n\n          3. Active cardiovascular disease including any of the following:\n\n               -  New York Heart Association (NYHA) Grade II or greater congestive heart failure\n\n               -  History of myocardial infarction or unstable angina within 6 months prior to Day\n                  1\n\n               -  History of stroke or transient ischemic attack within 6 months prior to Day 1\n\n          4. Acute or chronic respiratory disease\n\n          5. Acute or chronic bone/joint/muscular abnormalities compromising their ability to\n             exercise\n\n          6. Neurological conditions that affect balance and, or muscle strength\n\n          7. Dementia, altered mental status or any psychiatric condition prohibiting the\n             understanding or rendering of informed consent"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02130947", 
            "org_study_id": "LCCC  1339"
        }, 
        "intervention": {
            "arm_group_label": "Exercise Intervention Arm", 
            "intervention_name": "Exercise", 
            "intervention_type": "Behavioral"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Metastatic Castration Resistant Prostate Cancer", 
            "Prostate Cancer", 
            "mCRPC", 
            "Pilot Study", 
            "UNC Lineberger", 
            "Exercise"
        ], 
        "lastchanged_date": "May 6, 2014", 
        "link": [
            {
                "description": "Lineberger Comprehensive Cancer Center website", 
                "url": "http://unclineberger.org/"
            }, 
            {
                "description": "National Cancer Institute (NCI) website", 
                "url": "http://www.cancer.gov/"
            }
        ], 
        "location": {
            "contact": {
                "email": "corey_king@med.unc.edu", 
                "last_name": "Corey King", 
                "phone": "919-966-4432"
            }, 
            "facility": {
                "address": {
                    "city": "Chapel Hill", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27599"
                }, 
                "name": "Lineberger Comprehensive Cancer Center"
            }, 
            "investigator": {
                "last_name": "Anthony C Hackney, Ph.D., D.Sc.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized, Controlled Study of an Exercise Intervention Program for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Either Abiraterone or Enzalutamide", 
        "overall_contact": {
            "email": "corey_king@med.unc.edu", 
            "last_name": "Corey King", 
            "phone": "(919) 966-4432"
        }, 
        "overall_official": {
            "affiliation": "University of North Carolina", 
            "last_name": "Anthony C Hackney, Ph.D., D.Sc.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "DEXA (Dual-energy X-ray absorptiometry) scans will measure lean mass at baseline and after the 12-week intervention.", 
            "measure": "Change in lean mass between mCPRC patients undergoing a 12-week exercise intervention (intervention group) and mCPRC patients who do not undergo the  exercise intervention (control group)", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02130947"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "UNC Lineberger Comprehensive Cancer Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "UNC Lineberger Comprehensive Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}